OrganiGram Holdings Inc.

OrganiGram Holdings, Inc. engages in the production and sale of medical marijuana. It focuses on producing cannabis for patients and adult recreational consumers. The firm's brands include Adult Recreational and Medical. The company was founded on July 5, 2010 and is headquartered in Moncton, Canada.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OrganiGram Holdings, Inc. engages in the provision of high-quality, indoor-grown cannabis for patients and adult recreational consumers and developing international business partnerships to extend the company’s global footprint. Its brands include Edison, Big Bag O’ Buds, SHRED, Monjour, and Trailblazer. The company was founded on July 5, 2010 and is headquartered in Toronto, Canada.

Organigram reported Q4-2024 financial results earlier this week and show improved revenues, profit margins, net loss, and increased cash. The company announced the acquisition of Canadian private cannabis LP Motif Labs which will set Organigram in the top spot in Canada by market share. Organigram has increased its international footprint with an investment in Sanity Group in Germany and in Open Book Extracts in the US.

Organigram: Long Term Growth Improving With International And Domestic Cannabis Expansion (Rating Upgrade)

Organigram Holdings Inc. (NASDAQ:OGI ) Q3 2024 Earnings Conference Call December 18, 2024 8:00 AM ET Company Participants Max Schwartz - Director of IR Beena Goldenberg - CEO Tim Emberg - CCO Greg Guyatt - CFO Conference Call Participants Aaron Grey - Alliance Global Partners Frederico Gomes - ATB Capital Markets Pablo Zuanic - Zuanic & Associates Yewon Kang - Canaccord Genuity Operator Good morning. My name is Rob, and I will be your conference operator today.

Organigram Holdings Inc. (OGI) Q4 2024 Earnings Call Transcript

British American Tobacco

Legal cannabis company grows revenue and narrows its loss as it continues its acquisition push.

Canada's Organigram shops for U.S. pot businesses with backing from British American Tobacco

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer (“LP”) of cannabis, announced its results for the fourth quarter and twelve months ended September 30, 2024 (“Q4 Fiscal 2024” or “Fiscal 2024”). All financial information in this press release is expressed in Canadian dollars (“$”). Comparable Periods: The Company's results for Q4 Fiscal 2024 and Fiscal 2024 reflect the three-month and 12-month periods ended.

Organigram Reports Fourth Quarter and Fiscal 2024 Results

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its fourth quarter and fiscal 2024 ended September 30, 2024, on Wednesday, December 18, 2024, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Wednesday, December 18, 2024 Time: 8:0.

Organigram to Report Fourth Quarter and Fiscal 2024 Results on December 18, 2024

OrganiGram to pay up to C$100 million ($70.7 million) for vape and prerolled cannabis specialist Motif.

OrganiGram purchasing Motif Labs to become Canada's largest cannabis company by market share, as others retreat

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce the acquisition of 100% of the issued and outstanding shares of Motif Labs Ltd. (“Motif”), for upfront consideration of $90 million, consisting of $50 million in cash and $40 million of Organigram common shares priced based on the 30 day trading VWAP of $2.3210 on the Toronto Stock Exchange (“TSX”). In addition, Motif share.

Organigram Acquires Motif, Becoming Canada's Largest Cannabis Company by Market Share

Organigram's stock is undervalued, trading at a 22% discount to tangible book value, with strong growth projections and a solid financial outlook. The company has a high cash balance and no debt, bolstered by additional investment from British American Tobacco. Analysts expect revenue and adjusted EBITDA to grow significantly in FY25 and FY26, making the stock a compelling buy.

Organigram Could Soar In 2026

Agrify

Canopy Growth

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

Tilray Brands

With cannabis stocks showing steep losses this year on stalled legalization on the U.S. federal level, some companies in the sector are turning to the more thinly-regulated business of THC derived from hemp as a way to potentially excite Wall Street with new revenue streams.

Hemp-based THC revenue may make cannabis stocks more appealing—but there are risks

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is thrilled to finally launch Edison Sonics gummies, Organigram's inaugural product powered by FAST™, the Company's groundbreaking nanoemulsion technology and a first-to-market innovation. FAST™ products deliver up to ~50% faster onset and improved bioavailability delivering nearly double the cannabinoids at peak effect compared to traditional ed.

Organigram Launches FAST™ Nanoemulsion Gummies

Organigram's stock has surged 22% since my last analysis, outperforming the cannabis market, yet it remains a buy due to its promising chart and valuation. The fiscal Q3 report exceeded expectations with revenue up 25% and adjusted EBITDA turning positive, highlighting significant financial improvement and strong cash reserves. Analysts have raised their projections for FY25 and FY26, expecting higher revenue and adjusted EBITDA, reinforcing the stock's attractive valuation and growth potential.

Organigram: Why I Still Like It

Aurora Cannabis

Cronos Group

Many legal cannabis operators are working to keep pushing the boundaries of the industry. Innovation is key for any growing sector and cannabis is no different. Right now is a pivotal time for the cannabis industry as things are continuously changing. The climate of the sector and the success of companies can have a direct connection to how most marijuana stocks perform, especially during an election year where promises may come along from presidential candidates to better the industry.

3 Marijuana Stocks To Watch In The Stock Market Today

Zura Bio Ltd

SACRAMENTO, Calif.--(BUSINESS WIRE)--CPS HR Consulting, a leader in public sector HR consulting, is thrilled to announce a strategic partnership with GovInvest, the pioneer of compensation analytics technology for government agencies. This collaboration aims to combine CPS HR's renowned compensation consulting expertise with GovInvest's innovative software platform, offering unparalleled data confidence and decision-making capabilities. Highlights of the Partnership Best-in-Class Consulting + T.

CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today that on August 30, 2024, the Company closed the second of three tranches (the “Second Tranche”) of the previously announced C$124,559,674 follow-on strategic equity investment (the “Investment”) by BT DE Investments Inc. (the “Investor”), a wholly owned subsidiary of British American Tobacco plc (“BAT”). Pursuant to the Second Tra.

Organigram Closes Second Tranche of Previously Announced BAT Private Placement Investment

When it comes to finding top marijuana stocks to buy which companies would you choose? Now when going through this process there are some things to consider. For the most part, investing in all things is based on the same basic outline which is buy low sell high do your research create a game plan be patient, and try to take profits when you can.

Top Canadian Marijuana Stocks To Watch In 2024

Planet 13 Holdings Inc

The cannabis industry is buzzing with recent developments that could significantly impact its future. In July 2024, the U.S. Senate reintroduced the SAFE Banking Act to provide cannabis businesses with greater access to banking services. This move has reignited optimism in the sector, as it could alleviate some of the financial constraints faced by cannabis companies. Additionally, several states, including Florida and Ohio, are pushing forward with ballot initiatives that could legalize recreational marijuana by the end of the year. These legislative efforts, combined with the growing momentum for federal legalization, are fueling investor interest in marijuana penny stocks.

Next Week's Top Marijuana Stocks: Recent Big Gainers to Watch

Organigram reported improved 3Q 2024 results. The company holds lead position in the Canadian cannabis market and is increasing its international cannabis exports. OGI stock price trades below its NAV per share and is undervalued.

Organigram: Q3 2024 Earnings Show Improvement In Revenues And Net Income (Hold)

Organigram (NASDAQ: OGI ) stock is rising higher on Tuesday after the Canadian cannabis company released its most recent earnings report. The big news here is the company reporting C$41.06 million in revenue for its fiscal third quarter of the year.

Why Is Organigram (OGI) Stock Up 25% Today?

Organigram Holdings Inc. (NASDAQ:OGI ) Q3 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Max Schwartz - Director of Investor Relations Beena Goldenberg - Chief Executive Officer Greg Guyatt - Chief Financial Officer Conference Call Participants Aaron Grey - AGP Pablo Zuanic - Zuanic & Associates Frederico Gomes - ATB Capital Markets Yewon Kang - Canaccord Genuity Operator Good morning. My name is Keyla, and I'll be your conference operator today.

Organigram Holdings Inc. (OGI) Q3 2024 Earnings Call Transcript

OrganiGram Holdings Inc.'s stock OGI, -2.04% was up 4% in premarket trading Wednesday after the Canadian cannabis producer reported beter-than-expected revenue. OrganiGram swung to third-quarter net income of C$2.82 million ($2.05 million), from a loss of C$213.45 million in the year-ago quarter.

Organigram's stock rises as Canadian pot company's revenue tops analyst estimate

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the third quarter ended June 30, 2024 (“Q3 Fiscal 2024”). THIRD QUARTER HIGHLIGHTS Third quarter net revenue increased 25% to $41.1 million compared to $32.8 million in the same prior-year period Adjusted gross margin1 of $14.6 million or 36%, compared to $6.1 or 19% in the same prior- year period Net income of $2.8 mill.

Organigram Reports Third Quarter Fiscal 2024 Results

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), a leading licensed producer of cannabis, is pleased to unveil the preliminary results of its landmark clinical pharmacokinetic (PK) study conducted via the Product Development Collaboration (PDC) on its latest innovation, nanoemulsion technology. This patent-pending technology, branded FAST™ (Fast Acting Soluble Technology), will be the first innovation to be commercialized by Organigram leveraging the output of the PD.

Organigram Product Development Collaboration Completes Landmark Clinical Study on Nanoemulsion Technology

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its third quarter fiscal 2024 ended June 30, 2024, on Tuesday, August 13, 2024, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, August 13, 2024 Time: 8:00 am Eastern Time.

Organigram to Report Third Quarter Fiscal 2024 Results on August 13, 2024

Innovative Industrial Properties

Jazz Pharmaceuticals

Cannabis stocks initially sounded like a compelling opportunity when Canada became the first G7 nation to legalize recreational marijuana. At the time, the popular belief was that the U.S. would eventually follow suit.

The 3 Best Cannabis Stocks to Buy in August 2024

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced the appointment of Craig Harris to the Organigram Board of Directors effective today. Craig brings over 20 years of experience as a commercial lawyer, with a background in private practice and legal and regulatory engagement roles for various corporations. He is currently the Assistant General Counsel – Corporate & Commercial Legal.

News for OrganiGram Holdings Inc. Stock (OGI)